Stock Research: Metropolis Healthcare

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Metropolis Healthcare

NSEI:METROPOLIS INE112L01020
39
  • Value
    48
  • Growth
    53
  • Safety
    Safety
    27
  • Combined
    32
  • Sentiment
    51
  • 360° View
    360° View
    39
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Metropolis Healthcare Limited is an India-based company providing diagnostic services to patients, healthcare providers, and corporates. It operates in the pathology service industry, specializing in various pathological investigations including biochemistry, hematology, and microbiology, serving both B2B and B2C markets with over 4,000 tests. The company operates across India and Africa, with approximately 200 clinical laboratories and 4,300 service centers in 22 Indian states. In the last fiscal year, the company had a market cap of $1193 million, profits of $123 million, and revenue of $156 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 39 (better than 39% compared with alternatives), overall professional sentiment and financial characteristics for the stock Metropolis Healthcare are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Metropolis Healthcare. The consolidated Growth Rank has a good rank of 53, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 53% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 51, which means that professional investors are more optimistic about the stock than for 51% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 27, which means that the share price of Metropolis Healthcare is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 73% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 48, which means that the company has a financing structure that is riskier than those of 52% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 23 12 5
Growth
53 59 55 97
Safety
Safety
48 46 41 73
Sentiment
51 25 27 18
360° View
360° View
39 20 12 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
49 46 13 33
Opinions Change
50 8 50 37
Pro Holdings
n/a 12 56 47
Market Pulse
52 82 54 41
Sentiment
51 25 27 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 23 12 5
Growth
53 59 55 97
Safety Safety
48 46 41 73
Combined
32 25 19 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
20 26 10 3
Price vs. Earnings (P/E)
28 28 19 5
Price vs. Book (P/B)
22 16 19 5
Dividend Yield
31 28 39 46
Value
27 23 12 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
76 88 74 74
Profit Growth
88 55 24 60
Capital Growth
11 50 59 100
Stock Returns
39 43 55 85
Growth
53 59 55 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
56 54 52 70
Refinancing
19 19 17 33
Liquidity
53 60 56 75
Safety Safety
48 46 41 73

Similar Stocks

Discover high‑ranked alternatives to Metropolis Healthcare and broaden your portfolio horizons.

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Rede D'Or São Luiz

BOVESPA:RDOR3
Country: Brazil
Industry: Health Care Facilities
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.